<SEC-DOCUMENT>0001104659-25-011143.txt : 20250211
<SEC-HEADER>0001104659-25-011143.hdr.sgml : 20250211
<ACCEPTANCE-DATETIME>20250211065218
ACCESSION NUMBER:		0001104659-25-011143
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250211
DATE AS OF CHANGE:		20250211

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oculis Holding AG
		CENTRAL INDEX KEY:			0001953530
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94014
		FILM NUMBER:		25607635

	BUSINESS ADDRESS:	
		STREET 1:		BAHNHOFSTRASSE 7
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300
		BUSINESS PHONE:		617-937-2423

	MAIL ADDRESS:	
		STREET 1:		BAHNHOFSTRASSE 7
		CITY:			ZUG
		STATE:			V8
		ZIP:			6300

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BVCF IV, L.P.
		CENTRAL INDEX KEY:			0001761158
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 2606, TOWER I
		STREET 2:		NEW RICHPORT CENTER, 763 MENGZI ROAD
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200023
		BUSINESS PHONE:		86 (21) 6315 1313

	MAIL ADDRESS:	
		STREET 1:		SUITE 2606, TOWER I
		STREET 2:		NEW RICHPORT CENTER, 763 MENGZI ROAD
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			200023
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <previousAccessionNumber>0001193125-23-131200</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: BVCF IV, L.P. -->
          <cik>0001761158</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Ordinary Shares, CHF 0.01 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>11/27/2024</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001953530</issuerCik>
        <issuerName>Oculis Holding AG</issuerName>
        <issuerCusip>H5870P102</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>Bahnhofstrasse 7</com:street1>
          <com:city>Zug</com:city>
          <com:stateOrCountry>V8</com:stateOrCountry>
          <com:zipCode>CH-6300</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(d)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>BVCF IV, L.P.</reportingPersonName>
      <citizenshipOrOrganization>E9</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>2191810.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>2191810.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2191810.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.05</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>Notes to Rows 6, 8 and 9: See Item 2(a) below.

Notes to Row 11: Based on 43,367,703 Ordinary Shares issued and outstanding of the Issuer as of November 27, 2024.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>BEYEOTECH</reportingPersonName>
      <citizenshipOrOrganization>E9</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>2191810.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>2191810.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2191810.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.05</classPercent>
      <typeOfReportingPerson>CO</typeOfReportingPerson>
      <comments>Notes to Rows 6, 8 and 9: See Item 2(a) below.

Notes to Row 11: Based on 43,367,703 Ordinary Shares issued and outstanding of the Issuer as of November 27, 2024.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>BVCF IV GP, Ltd.</reportingPersonName>
      <citizenshipOrOrganization>E9</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>2191810.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>2191810.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2191810.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.05</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>Notes to Rows 6, 8 and 9: See Item 2(a) below.

Notes to Row 11: Based on 43,367,703 Ordinary Shares issued and outstanding of the Issuer as of November 27, 2024.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Zhi Yang</reportingPersonName>
      <citizenshipOrOrganization>F4</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>2191810.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>2191810.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2191810.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.05</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>Notes to Rows 6, 8 and 9: See Item 2(a) below.

Notes to Row 11: Based on 43,367,703 Ordinary Shares issued and outstanding of the Issuer as of November 27, 2024.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Oculis Holding AG</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>Bahnhofstrasse 7 Zug, V8, CH-6300</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This statement is filed by (i) BVCF IV, L.P. ("Fund"), a limited partnership incorporated under the laws of the Cayman Islands, (ii) BEYEOTECH ("Beyeotech"), a company organized and existing under the laws of the Cayman Islands, (iii) BVCF IV GP, Ltd. ("GP"), a limited company incorporated under the laws of the Cayman Islands, and (iv) Mr. Zhi Yang, a director and sole shareholder of GP (Fund, Beyeotech, GP and Mr. Zhi Yang are collectively referred to as the "Reporting Persons").

Beyeotech directly holds the 2,191,810 Ordinary Shares being reported in this statement. Beyeotech is a wholly-owned subsidiary of Fund, GP is the general partner of Fund and Mr. Zhi Yang is the sole shareholder and director of GP.

GP, by virtue of it being the general partner of Fund, may be deemed to have voting control and investment discretion over the securities held by Beyeotech.

Mr. Zhi Yang, by virtue of being the director and sole shareholder of GP, may be deemed to have voting control and investment discretion over the securities held by Beyeotech.

Each of the Reporting Persons has entered into a Joint Filing Agreement, dated April 28, 2023, pursuant to which such Reporting Persons have agreed to file this statement jointly in accordance with the provisions of 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The address of the principal business office of Beyeotech is 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands. The address of the principal business office of each of Fund, GP and Mr. Zhi Yang is 763 Mengzi Road, Suite 2606, Shanghai, China 200023.</principalBusinessOfficeOrResidenceAddress>
        <citizenship>See Row 4 of each cover page.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>See Row 9 of each cover page.</amountBeneficiallyOwned>
        <classPercent>See Row 11 of each cover page.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>See Row 5 of each cover page.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>See Row 6 of each cover page.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>See Row 7 of each cover page.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>See Row 8 of each cover page.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>Y</notApplicableFlag>
      </item10>
    </items>
    <exhibitInfo>Joint Filing Agreement dated April 28, 2023

https://www.sec.gov/Archives/edgar/data/1761158/000119312523131200/d499516dex991.htm</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>BVCF IV, L.P.</reportingPersonName>
      <signatureDetails>
        <signature>By: BVCF IV GP, Ltd., its general partner /s/ Zhi Yang</signature>
        <title>Zhi Yang/Director</title>
        <date>02/11/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>BEYEOTECH</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Bernard Yang Feng</signature>
        <title>Bernard Yang Feng/Director</title>
        <date>02/11/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>BVCF IV GP, Ltd.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Zhi Yang</signature>
        <title>Zhi Yang/Director</title>
        <date>02/11/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Zhi Yang</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Zhi Yang</signature>
        <title>Zhi Yang</title>
        <date>02/11/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
